Skip to main content

Table 3 Data on biomarkers

From: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

DRUP-ID

Tumour type

Pre-enrolment based on

Baseline WGS

Baseline RNA

BOR

  

Confirmed Lynch (germline mutation)

IHC

Molecular analysis

WGS available

MSI

MMR mutations

B2M/JAK1/JAK2/STAT1

TMB (mut/Mb)

RNA available

 

1010121

Endometrium

 

MLH1/PMS2 loss

 

Yes

No

  

3.6

No

PD

1010122

CRC

 

MLH1/PMS2 loss

 

Yes

Yes

 

STAT1 p.R70C

193.2

Yes

PR

1010123

Small intestine

Yesa

MSH2/MSH6 loss

 

Yes

Yes

MSH6;MSH2;MLH1

STAT1 p.D674N

274.7

Yes

SD

1010142

Bile duct

 

MLH1/PMS2 loss

 

Yes

Yes

MLH1b;MSH6;MLH1b;

 

48.9

No

SD

1010148

Breast

  

MSI by WGS (msIndels 45.0)

Yes

Yes

MSH2b

JAK1 p.K860Nfs*16;p.P430Rfs*2, JAK2 p.L224*

122.6

Yes

PD

1010167

Endometrium

 

MLH1/PMS2 loss

 

Yes

Yes

 

JAK1 p.K860Nfs*16

44.8

No

NE

1010211

CRC

Yes (MSH6)

MSH6/PMS2 loss

 

Yes

Yes

PMS2;MSH6

B2M p.Q22*

60.0

Yes

SD

1020053

CRC

 

MLH1/PMS2 loss

MSI by PCR (pentaplex)

Yes

Yes

MSH6;MSH2;MLH1

JAK1 p.S771R

366.0

No

NE

1020056

Glioblastoma

Yes (MSH2)

  

No

NA

NA

NA

NA

No

PD

1040016

Small intestine

Yes (MLH1)

 

MSI by PCR (8 marker panel)

Yes

Yes

MSH6

B2M p.M1?;p.T93Lfs*10, JAK1 p.K860Nfs*16;p.P430Rfs*2

213.3

No

PD

1050048

Bile duct

Yesa

MLH1/PMS2 loss

 

Yes

Yes

PMS2

B2M p.S16Afs*27,

JAK2 p.R1113H

127.0

Yes

PR

1050049

Prostate

  

MSI by WGS (msIndels 35.6)

Yes

Yes

MSH2b

JAK1 p.K860Nfs*16;p.P430Rfs*2

65.0

Yes

PD

1070080

CRC

 

MLH1/PMS2 loss

MSI by PCR (pentaplex)

Yes

Yes

MSH2;PMS2

 

145.6

No

SD

1070085

Stomach

  

MSI by NGS (56 marker panel)

Yes

Yes

PMS2

 

105.8

Yes

PD

1070119

Pancreas

Yes (MSH6)

MSH6 loss

 

Yes

No

  

21.7

No

PD

1080031

Bile duct

 

MLH1/PMS2 loss

 

Yes

Yes

  

80.0

Yes

PD

1090033

CRC

 

MLH1/PMS2 loss

 

No

NA

NA

NA

NA

NA

PD

1110009

Small intestine

 

MSH2/MSH6 loss

MSI by PCR (pentaplex)

No

NA

NA

NA

NA

NA

PR

1130003

Endometrium

Yes (MSH2)

  

No

NA

NA

NA

NA

NA

PR

1130004

NEC

 

MLH1 loss

 

No

NA

NA

NA

NA

NA

SD

1220010

Stomach

 

MLH1/PMS2 loss

 

No

NA

NA

NA

NA

NA

PD

1230004

CRC

 

MLH1/PMS2 loss

 

Yes

Yes

MSH6

B2M p.S16Ffs*29;p.S16Afs*27

293.2

Yes

CR

1260001

Stomach

 

MLH1/PMS2 loss

 

No

NA

NA

NA

NA

NA

CR

1330020

Breast

  

MSI by WGS (msIndels 63.5)

Yes

Yes

MSH6

JAK1 p.K860Nfs*16;p.P430Rfs*2,

STAT1 p.A479V

294.0

Yes

PD

1340016

CRC

Yes (MSH2)

  

Yes

Yes

MSH2

 

217.8

Yes

SD

1340017

CRC

 

MLH1/PMS2 loss

 

Yes

Yes

MSH6; PMS2

B2M p.M1?;p.L15Ffs*41, JAK1 p.K860Nfs*16

247.7

Yes

CR

  1. Data on biomarkers of enrolled patients (n = 26)
  2. Abbreviations: BOR best overall response, CR complete response, CRC colorectal cancer, IHC immunohistochemistry, MMR mismatch repair, Mut/Mb mutations per megabase, MSI microsatellite instability, msIndels microsatellite-instable indels, NA not applicable, NE non-evaluable, NEC neuroendocrine carcinoma, NGS next generation sequencing, PCR polymerase chain reaction, PD progressive disease, PR partial response, SD stable disease, TMB tumour mutation burden, WGS whole genome sequencing
  3. aGermline mutation not known, bbi-allelic loss of heterozygosity of that gene
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us